Skip to main content

Table 1 Demographic and clinicopathologic variables of 6753 patients with advanced gastric cancer in the training and validation sets

From: A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer

Variables SYSUCC training set (n = 2169) CMU validation set (n = 2353) TJMU validation set (n = 2231) P value
Age (years)a 59 (50–66) 60 (52–68) 59 (50–68) < 0.001
Sex 0.049
 Male 1510 (69.6) 1714 (72.8) 1576 (70.6)
 Female 659 (30.4) 639 (27.2) 655 (29.4)
Tumor location < 0.001
 Antrum 813 (37.5) 1260 (53.5) 787 (35.3)
 Body 376 (17.3) 317 (13.5) 288 (12.9)
 Cardia/fundus 894 (41.2) 644 (27.4) 746 (33.4)
 Whole stomach 86 (4.0) 132 (5.6) 410 (18.4)
Tumor size (cm)a 4.5 (3.0–6.0) 5.0 (3.5–6.5) 5.0 (3.5–7.0) < 0.001
Lauren classification < 0.001
 Intestinal 766 (35.3) 1166 (49.6) 859 (38.5)
 Diffuse 1403 (64.7) 1187 (50.4) 1372 (61.5)
Lymphatic/venous invasion < 0.001
 No 1917 (88.4) 1556 (66.1) NA
 Yes 252 (11.6) 797 (33.9) NA
T category < 0.001
 T2 298 (13.7) 933 (39.7) 195 (8.7)
 T3 472 (21.8) 602 (25.6) 186 (8.3)
 T4a 1224 (56.4) 672 (28.6) 1673 (75.0)
 T4b 175 (8.1) 146 (6.2) 177 (7.9)
No. of metastatic lymph nodesa 3 (0–8) 3 (0–8) 2 (0–7) < 0.001
No. of lymph nodes dissecteda 21 (13–29) 27 (18–36) 17 (11–24) < 0.001
Metastatic lymph node ratioa 0.17 (0–0.43) 0.11 (0–0.33) 0.15 (0–0.46) < 0.001
  1. SYSUCC Sun Yat-sen University Cancer Center; CMU Chinese Medical University; TJMU Tianjin Medical University
  2. aThe terms are continues variables and their values are presented as median followed by 95% confidential interval in parentheses; other values are presented as number of patients followed by percentage in parentheses